FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Klencke Barbara
  2. Issuer Name and Ticker or Trading Symbol
Sierra Oncology, Inc. [SRRA] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Medical Officer
(Last)
(First)
(Middle)
C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DR., SUITE 110		 3. Date of Earliest Transaction (Month/Day/Year)
07/01/2022
(Street)

SAN MATEO, CA 94404		 4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2022   D   10,000 D $ 55 0 D  
Common Stock 07/01/2022   D   5,000 D $ 55 0 I By spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy $ 268.2 07/01/2022   D     11,744   (1) 06/10/2025 Common Stock 11,744 $ 0 (2) 0 D  
Stock Option (right to buy) $ 263.2 07/01/2022   D     2,061   (3) 03/08/2016 Common Stock 2,061 $ 0 (2) 0 D  
Stock Option (right to buy) $ 72.8 07/01/2022   D     11,399   (4) 09/30/2026 Common Stock 11,399 $ 0 (2) 0 D  
Stock Option (right to buy) $ 58 07/01/2022   D     1,749   (5) 03/06/2027 Common Stock 1,749 $ 0 (2) 0 D  
Stock Option (right to buy) $ 94.4 07/01/2022   D     4,508   (6) 03/06/2028 Common Stock 4,508 $ 0 (2) 0 D  
Stock Option (right to buy) $ 78.4 07/01/2022   D     4,999   (7) 03/04/2029 Common Stock 4,999 $ 0 (2) 0 D  
Stock Option (right to buy) $ 13.31 07/01/2022   D     167,091   (8) 02/25/2030 Common Stock 167,091 $ 0 (9) 0 D  
Stock Option (right to buy) $ 12.15 07/01/2022   D     49,000   (10) 08/12/2030 Common Stock 49,000 $ 0 (9) 0 D  
Stock Option (right to buy) $ 16.73 07/01/2022   D     30,000   (11) 03/15/2031 Common Stock 30,000 $ 0 (9) 0 D  
Stock Option (right to buy) $ 31.54 07/01/2022   D     50,000   (12) 03/14/2032 Common Stock 50,000 $ 0 (9) 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Klencke Barbara
C/O SIERRA ONCOLOGY, INC.
1820 GATEWAY DR., SUITE 110
SAN MATEO, CA 94404		       Chief Medical Officer  

Signatures

 /s/ Mary Christina Thomson, Attorney-In-Fact for Barbara Klencke   07/01/2022
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The option fully vested on June 11, 2019.
(2) Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
(3) The option fully vested on January 1, 2020.
(4) The option fully vested on September 30, 2019.
(5) The option fully vested on January 1, 2021.
(6) The option fully vested on January 1, 2022.
(7) The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date.
(8) The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
(9) Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
(10) On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
(11) The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
(12) The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.